Kim M, Kim SC, Kim J, Kim BH
Biologics get twelve years of reference product exclusivity under the Biologics Price Competition and Innovation Act (BPCIA), plus a potential four-year first biosimilar exclusivity for the first approved biosimilar [2]
We make no medical claims as to the benefits of any of our products to improve medical conditions
Application of luteolin nanomicelles anti-glioma effect with improvement in vitro and in vivo
These specialists understand how drug-induced eye problems typically present and stay updated on new evidence regarding GLP-1 receptor agonist-associated vision changes
The number of pending lawsuits in MDL 3094, Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation has been steadily increasing as more people allege injuries such as gastrointestinal disorders, blood clots, and vision loss were caused by their use of Ozempic